Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones by Ming-Hsiu Yang Su

Total Page:16

File Type:pdf, Size:1020Kb

Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones by Ming-Hsiu Yang Su Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones By Ming-Hsiu Yang Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy Chairperson Ryan A. Altman Michael D. Clift Apurba Dutta Michael F. Rafferty Jon A. Tunge Date Defended: April 26, 2017 The Dissertation Committee for Ming-Hsiu Yang certifies that this is the approved version of the following dissertation: Synthetic Strategies to Access Biologically Important Fluorinated Motifs: Fluoroalkenes and Difluoroketones Chairperson Ryan A. Altman Date Approved: April 26, 2017 ii Abstract Ming-Hsiu Yang Department of Medicinal Chemistry, April 2017 The University of Kansas Fluorine plays an important role in drug design, because of some unique features imparted by fluorine. The incorporation of fluorine into small molecules can modulate molecular physicochemical properties, metabolic stability, lipophilicity, and binding affinity to the target proteins. However, few fluorinated molecules are biosynthesized by enzymes. This means incorporating fluorine into the molecules relies on synthetic methods. Thus, efficient synthetic strategies to access the molecules bearing a variety of privileged fluorinated moieties are important for drug discovery. Fluoroalkenes are an isopolar and isosteric mimic of an amide bond with distinct biophysical properties, including decreased H-bond donating and accepting abilities, increased lipophilicity, and metabolic stability. Moreover, fluoroalkenes can also serve as probes for conducting conformational analyses of amides. These potential applications require the development of efficient methods to access fluoroalkenes. In chapter 2, a Shapiro fluorination strategy to access peptidomimetic fluoroalkenes is demonstrated. The Shapiro fluorination reactions convert a ketone into a fluoroalkene in one or two steps. Moreover, this method uses inexpensive and readily available reagents, and no transition metals are involved in the reactions. Thus, it provides an operation-simple alternative to access fluoroalkenes in medicinal chemistry. ,-difluoroketones represent a privileged substructure in medicinal chemistry, and serves as inhibitors to many hydrolytic enzymes, such as serine and aspartyl proteases. From chapters 3 to 5, palladium-catalyzed decarboxylative methods are developed for accessing -alkyl- and -aryl-,- difluoroketones. This decarboxylative strategy overcomes two major challenges associated with alkylation reactions of ,-difluoroketone enolates. Chapter 3 demonstrates that decarboxylation regioselectively generates ,-difluoroketone enolates, which are difficult to access by base iii deprotonation. Moreover, palladium catalysis enables the coupling of the ,-difluoroketone enolate with benzylic electrophiles to form a key C()–C(sp3) bond. In chapter 4, an orthogonal catalytic system is developed for accessing linear and branched -allyl-,-difluoroketones. Two distinct mechanisms are involved in the formation of the regioisomers. Chapter 5 describes a base-mediated selective para-C–H difluoroalkylation of arenes, which represents a different strategy for para-C–H functionalization of arenes compared to the known methods. These decarboxylative coupling reactions provide structurally diverse ,-difluoroketone derivatives, and should be useful for accessing potential biological probes and therapeutics. iv Acknowledgements Six years of graduate study is not an easy thing. I feel blessed to stay in KU for my graduate career, and have enjoyable and knowledgeable life. I would like to express my deepest gratitude to many people whom I have worked with, and have received help from. Without their assistance, I would never have been able to finish my graduate study and obtain the degree. First and foremost, I would like to thank my advisor, Professor Ryan Altman, for accepting me into his lab, and providing me with a good atmosphere for doing research. His guidance in poster and oral presentation, academic writing, thinking and solving scientific problems, and engaging me in research ideals help me to become a well-educated and professional chemist. His demand on high-quality of work in all my endeavors makes me a scientist. I am grateful for his patience as I know it is very hard to instruct me, an international student whose native language is not English. I would like to thank my committee members, Professors Michael Clift, Apurba Dutta, Michael Rafferty, and Jon Tunge, for their time, support, and valuable insights. Their constructive feedback makes this dissertation much perfect. Special thanks go to Dr. Justin Douglas and Sarah Neuenswander for analyses of NMR spectroscopy and Dr. Williams Todd, Lawrence Seib, and Bob Drake for analyses of Mass spectrometry. Their support and help makes my research proceed more smoothly. I would like to thank all the people who contributed in some way to the projects included in this dissertation. To my first partner, Siddharth, thanks for the help in the Shapiro fluorination project. To Doug, thank you for the help in the allylation project of -difluoroketone enolates and useful suggestions on research. To Jordan and Niusha, thanks for working with me in the benzylation project of -difluoroketone enolates. To Dr. Francisco de Azambuja, thanks for the assistance and insightful discussion in the para-C–H difluoroalkylation project. I would like to thank the past and present group members for all of the help along the way, especially Brett for helping me solve lab related problems as well as giving useful suggestions on research and manuscript writing. v I would like to thank my classmates, Anuj, Leah, Gaurav, Sanket, Molly, Rakesh, and Cameron, for the help on classes and life. I would like to thank Huiyong, Ning, and Linqui for helping me solve daily life problems and live comfortably during my graduate study. I would like to thank group members in the laboratories of Professors Aubé, Prisinzano, Blagg, Paul, Tunge, and Clift for supporting research chemicals and lab equipment. I would like to thank my parents for their love, support, and understanding. Finally, I thank God for giving me the courage and strength to go through the good and bad times of my graduate study, and leading me on a correct track toward my goals. vi Table of Contents Chapter 1. Importance and Application of Fluorine in Drug Design 1.1 The Effect of F on Physicochemical Properties……………………………………………….………..1 1.2 The Effect of F on Lipophilicity………………………………………………………………………..5 1.3 The Effect of F on Molecular Conformations…………………………………………………………..6 1.4 The Effect of F on Metabolic or in vivo Stability……………………………………………………....9 1.5 The Effect of F on Protein-Ligand Binding Interactions…………………………………………...…13 1.6 Fluorine as a Key Component of Drugs…………………………………………………………….…15 1.7 Conclusion………………………………………………………………………………………….....17 1.8 References for Chapter 1…………………………………………………………………………...….18 Chapter 2. Preparation of Peptidomimetic Fluoroalkenes via a Shapiro Reaction 2.1 Introduction to Fluoroalkenes…………………………………………………………………………22 2.2 Literature Review to Access Fluoroalkenes………………………………………………………..…24 2.3 Shapiro Fluorination to Access Fluoroalkenes……………………..…………………..………….….38 2.4 Conclusion…………………………………………………………………………………………….47 2.5 References for Chapter 2………………………………………………………………………………48 Chapter 2 Appendix: Experimental Procedures and Spectral Analyses……………...…………………...54 Chapter 3. Palladium-Catalyzed Decarboxylative Benzylation of ,-Difluoroketone Enolates 3.1 Introduction to ,-Difluoroketones……………………………………………………………….....80 3.2 Literature Review to Access ,-Difluoroketones…………………………………………….……..83 3.3 Challenges to Access -Alkyl-,-Difluoroketones………………………………………………….89 3.4 Palladium-Catalyzed Decarboxylative Difluoroalkylation to Access -Benzyl-,-difluoroketones.90 3.5 Conclusion…………………………………………………………………………………………….98 3.6 References for Chapter 3………………………………………………………………………………99 Chapter 3 Appendix: Experimental Procedures and Spectral Analyses………..……………...………...103 Chapter 4. Ligand-Controlled Regiodivergent Palladium-Catalyzed Decarboxylative Allylation of ,-Difluoroketone Enolates 4.1 Introduction to Transition Metal-Catalyzed Decarboxylative Allylation…………………..………..156 4.2 Development to Access -Allyl-,-Difluoroketones………………………………………………158 4.3 Palladium-Catalyzed Decarboxylative Difluoroalkylation to Access -Allyl-,-difluoroketones...160 4.4 An Orthogonal Set of Palladium-Catalyzed Allylation Reactions of ,-Difluoroketone Enolates...162 vii 4.5 Conclusion………………………………………………………………………………………..….175 4.6 References for Chapter 4……………………………………………………………………………..176 Chapter 4 Appendix: Experimental Procedures and Spectral Analyses……………...………………….179 Chapter 5. Palladium-Catalyzed para-C–H Difluoroalkylation of Arenes via Decarboxylation of Benzyl ,-Difluoro--keto-esters 5.1 Introduction to Selective para-C–H Functionalization of Arenes…………………………………..227 5.2 Base-Promoted Selective para-Difluoroalkylation of Arenes…………………………………..……232 5.3 Conclusion……………………………………………………………………………………….…..246 5.4 References for Chapter 5……………………………………………………………………………..247 Chapter 5 Appendix: Experimental Procedures and Spectral Analyses…………...………………….....250 viii List of Figures Chapter 1 Figure 1.1. Effect of Fluorination on Physicochemical Properties and Applications on Drug Design….…5 Figure 1.2. Fluorine Substitution Modifies Molecular Lipophilicity…………………………………….6 Figure 1.3.
Recommended publications
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Survey and Risk Assessment of Chemical Substances in Deodorants
    Survey and risk assessment of chemical substances in deodorants Suresh C. Rastogi & Gitte Hellerup Jensen National Environmental Research Institute Jeanne Duus Johansen National Allergy Research Centre Survey of Chemical Substances in Consumer Products, No. 86 2007 The Danish Environmental Protection Agency will, when opportunity offers, publish reports and contributions relating to environmental research and development projects financed via the Danish EPA. Please note that publication does not signify that the contents of the reports necessarily reflect the views of the Danish EPA. The reports are, however, published because the Danish EPA finds that the studies represent a valuable contribution to the debate on environmental policy in Denmark. Contents SAMMENFATNING 5 SUMMARY 7 1 INTRODUCTION 11 2 MARKET SURVEY AND PRODUCT SAMPLING 13 2.1 MARKET SURVEY 13 2.2 LEGISLATION 15 2.3 SAMPLING OF PRODUCTS AND CONTROL OF LABELLING 15 2.4 SELECTION OF PRODUCTS FOR ANALYSIS 18 3 ANALYSIS 19 3.1 MATERIALS 19 3.2 ANALYSIS 19 3.2.1 Sample preparation 19 3.2.2 Analysis of fragrance substances 19 3.2.3 Analysis of triclosan 20 4 RESULTS 21 5 RISK ASSESSMENT 27 5.1 DEODORANTS AND CONTACT ALLERGY 27 5.2 RISK ASSESSMENT – IN GENERAL 27 5.3 THE SELECTED FRAGRANCE SUBSTANCES 28 5.3.1 HYDOXYISOHEXYL 3-CYCLOHEXENE CARBOXALDEHYDE (HICC) 28 5.3.2 HYDROXYCITRONELLAL 32 5.3.3 ISOEUGENOL 33 5.3.4 CINNAMAL/CINNAMYL ALCOHOL 34 5.4 FARNESOL 35 5.5 COMMENTS CONCERNING OTHER FRAGRANCE SUBSTANCES 35 5.6 ALLERGEN LOAD OF FRAGRANCE SUBSTANCES 36 5.7 TRICLOSAN 36 6 DISCUSSION 38 7 REFERENCES 43 ANNEX 1 49 3 4 Sammenfatning Deodoranter anvendes dagligt af store dele af befolkningen og kan indeholde ingredienser, som visse duftstoffer og konserveringsmidler, der er hyppige år- sager til hudallergi.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0127257 A1 Schiemann Et Al
    US 2014O127257A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0127257 A1 Schiemann et al. (43) Pub. Date: May 8, 2014 (54) DERMATOLOGICALLY EFFECTIVE YEAST Publication Classification EXTRACT (51) Int. Cl. (75) Inventors: Yvonne Schiemann, Essen (DE); Mike A61E36/064 (2006.01) Farwick, Essen (DE); Thomas Haas, CI2P I/02 (2006.01) Muenster (DE); Mirja Wessel, Bochum A61E36/06 (2006.01) (DE) (52) U.S. Cl. CPC ............... A61K 36/064 (2013.01); A61K 36/06 (73) Assignee: EVONIK DEGUSSA GMBH, Essen (2013.01); CI2P I/02 (2013.01) (DE) USPC ...................................... 424/195.16; 435/171 (21) Appl. No.: 14/128,244 (22) PCT Fled: Jun. 14, 2012 (57) ABSTRACT (86) PCT NO.: PCT/EP2012/061263 The invention relates to a method for producing a dermato S371 (c)(1), logically active yeast extract, comprising the following steps: (2), (4) Date: Dec. 20, 2013 providing a preculture of the yeast cells, culturing the cells for (30) Foreign Application Priority Data at least fifteen minutes at a pH of 1.8-4, harvesting the cells and lysing the cells, and a yeast extract produced thereby and Jun. 29, 2011 (EP) .................................. 11171953.0 products comprising said yeast extract. Patent Application Publication May 8, 2014 Sheet 1 of 3 US 2014/O127257 A1 -0-Yarrowia------------ lipolytica -- Pichia CBS 1991 - A - Saccharomyces Cerevisiae Fig. 1 US 2014/O127257 A1 May 8, 2014 DERMATOLOGICALLY EFFECTIVE YEAST skin. Against the background of consumers’ uncertainty with EXTRACT respect to genetic engineering techniques, there is a particular demand for corresponding agents that can be regarded, 0001.
    [Show full text]
  • Breast Cysts and Aluminium-Based Antiperspirant Salts
    Breast cysts and aluminium-based antiperspirant salts Article Published Version Creative Commons: Attribution 4.0 (CC-BY) Open access Darbre, P. (2019) Breast cysts and aluminium-based antiperspirant salts. Clinical Dermatology: Research and Therapy, 2 (1). 128. Available at http://centaur.reading.ac.uk/88553/ It is advisable to refer to the publisher’s version if you intend to cite from the work. See Guidance on citing . Publisher: Scientific Literature All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the End User Agreement . www.reading.ac.uk/centaur CentAUR Central Archive at the University of Reading Reading’s research outputs online Clinical Dermatology: Research And Therapy Special Issue Article “Breast Cyst” Research Article Breast cysts and aluminium-based antiperspirant salts Philippa D Darbre* School of Biological Sciences, University of Reading, UK ARTICLE INFO ABSTRACT On the basis that aluminium-based antiperspirant salts are designed to block apocrine Received Date: July 17, 2019 Accepted Date: September 23, 2019 sweat ducts of the axilla, and that breast cysts result from blocked breast ducts in the Published Date: September 30, 2019 adjacent region of the body, it has been proposed that breast cysts may arise from KEYWORDS antiperspirant use if sufficient aluminium is absorbed into breast tissues over long-term usage. This review collates evidence that aluminium can be absorbed from dermal Aluminium application of antiperspirant salts and describes studies measuring levels of aluminium Breast cancer Breast cysts in breast tissues, including in breast cyst fluids.
    [Show full text]
  • Shapiro Reaction
    MANA TV programme SHAPIRO REACTION P. Kiran Kumar Lecturer in Chemistry SGA Government Degree College Yellamanchili SHAPIRO REACTION Treatment of tosyl hydrazone of an aldehyde or a ketone with a strong base leads to the formation of vinyl anion which on hydrolysis given an olefin. Hydrazine Phenyl Hydrazine Tosyl hydrazide (p-Toluenesulfonyl hydrazide) Tosyl hydrazone Formed by Nucleophilic addition between aldehyde or ketone and Tosyl hydrazide (p-Toluenesulfonyl hydrazide) and subsequent loss of carbonyl oxygen Mechanism Deprotonation of Tosyl hydrazone with a strong base to form Hydrazone aza enolate. Elimination of aryl sulfinate gives an unstable anion. Loss of Nitrogen leads to vinyl anion Hydrazone aza enolate unstable anion Vinyl anion Vinyl anions can be trapped by number various electrophiles 1. Hydrolysis gives an Alkene 2. Reaction with D2O gives Deuterated Alkene 3. Reaction with CO2 gives α, β-unsaturated acid 4. Reaction with formaldehyde gives Primary alcohol Vinyl anionsanions can can be be trapped trapped by by number number various various electrophiles – –Cont’dCont’d 5. Reaction with DMF gives an α, β-unsaturated aldehyde 6. Reaction with Alkyl chloride gives an Alkyl substituted alkene 7. Reaction with (CH3)3SiCl gives a Vinyl Silane Shapiro reaction involving cyclic ketones Cyclohexanone Shapiro reaction involving cyclic ketones Mechanism Mechanisms Mechanisms Mechanism Shapiro reaction involving unsymmetrical ketones unsymmetrical ketones gives predominantly less substituted olefins Shapiro reaction involving unsymmetrical ketones Removal of proton from the more substituted carbon atom Not formed Stability of the carbanion: secondary versus tertiary Secondary carbanion Tertiary carbanion Secondary carbanion more stable than primary carbanion.
    [Show full text]
  • Syllabus CHEM 6352 2014
    CHEM 6352 Organic Reactions & Synthesis Fall 2014 Jeremy A. May Office: 5025 SERC Office hours: T/Th 10-11 am or by appointment (email me) Email: [email protected] Website: http://mynsm.uh.edu/groups/maygroup/wiki/b24dc/Classes.html Lectures: 154 Fleming Tuesdays and Thursdays 8:30–10:00. August 26–December 6, 2014. Homework Session Saturdays 3:00 pm to 5:30 pm in Fleming 154/160/162. No class November 27–29, 2014 (Thanksgiving recess); Oct. 31st is last day to withdraw Optional Texts (on reserve at MD Anderson Library) Zweifel, G.; Nantz, M. “Modern Organic Synthesis: An Introduction” March, J. “Advanced Organic Chemistry” Corey, E. J.; Cheng, X.-M. “The Logic of Chemical Synthesis” Warren, S. “Designing Organic Syntheses: A Programmed Introduction to the Synthon Approach” Kürti, L.; Czakó, B. “Strategic Applications of Named Reactions in Organic Synthesis” Grossman, R. “The Art of Writing Reasonable Organic Reaction Mechanisms” Model Sets: Students are strongly encouraged to purchase at least one set. HGS biochemistry molecular model sets are recommended and are available at Research Stores in the Old Science Building. Other relevant texts and references: Greene; Wuts. “Protective Groups in Organic Synthesis” Nicolaou, K.C.; Sorensen, E. “Classics in Total Synthesis” Nicolaou, K.C.; Snyder, S. “Classics in Total Synthesis II” Larock, R. C. "Comprehensive Organic Transformations" Hartwig, J. “Organotransition Metal Chemistry: From Bonding to Catalysis” Tsuji, J. “Palladium Reagents and Catalysts” Hegedus, L. “Transition Metals in the Synthesis of Complex Organic Molecules” Problem Sets: Problem Sets will be distributed on Tuesdays (or before) and are due by the next Saturday at the Homework Session.
    [Show full text]
  • Review of the Regulation of Products at the Interface Between Cosmetics and Therapeutic Goods
    PO Box 100, Woden ACT 2606, Australia Review of the regulation of products at the interface between cosmetics and therapeutic goods 18 March 2005 Review of the regulation of products at the interface between cosmetics and therapeutic goods March 2005 Prepared for the TGA by David B Newgreen Review of the regulation of products at the interface between cosmetics and therapeutic goods CONTENTS ABBREVIATIONS ..........................................................................................................ii ACKNOWLEDGMENTS .............................................................................................. iii TERMS OF REFERENCE ..............................................................................................iv SUMMARY.....................................................................................................................vi RECOMMENDATIONS..................................................................................................x 1. INTRODUCTION ......................................................................................................13 2. OVERVIEW OF THE REGULATION OF MEDICINES AND COSMETICS IN AUSTRALIA AND NEW ZEALAND ....................................................................23 2.1 AUSTRALIA......................................................................................................23 2.2 NEW ZEALAND ...............................................................................................33 3. OVERVIEW OF THE REGULATION OF MEDICINES AND COSMETICS IN
    [Show full text]
  • Therapeutic Review Exploring Antimicrobial Potential of Hydrazones As Promising Lead
    Available online a t www.derpharmachemica.com Scholars Research Library Der Pharma Chemica, 2011, 3(1):250-268 (http://derpharmachemica.com/archive.html) ISSN 0975-413X CODEN (USA): PCHHAX Therapeutic Review Exploring Antimicrobial Potential of Hydrazones as Promising Lead Goldie Uppal, Suman Bala*, Sunil Kamboj and Minaxi Saini M.M. College of Pharmacy, Maharishi Markandeshwar University, Ambala, Haryana, India ______________________________________________________________________________ ABSTRACT This review includes detailed study of structures of various hydrazones synthesized and evaluated for their antimicrobial activity. Hydrazone is a class of organic compounds with structure R 1R2C=NNH 2. Hydrazones containing an azomethine -NHN=CH- proton which leads to an important class of compounds for new drug development. Hydrazones are present in many of the bioactive heterocyclic compounds that are of very important use because of their various biological and clinical applications. Therefore, many researchers have synthesized these compounds as target structures and evaluated their antimicrobial activities. These observations have been guiding for the development of new hydrazones that possess varied biological activities. Key Words: Hydrazones, Hydrazide, Antifungal Activity, Antimicrobial Activity. ______________________________________________________________________________ INTRODUCTION The need to design new compounds to deal with the resistant strains has become one of the most important areas of research today. Hydrazone is a versatile moiety that exhibits a wide variety of biological activities. A hydrazone is a class of organic compounds with the structure R1R2C=NNH 2. Hydrazones are basically related to ketones and aldehydes. Hydrazones are formed by the replacement of the oxygen of carbonyl compounds with the -NNH 2 functional group. Hydrazones act as reactants in many important reactions e.g.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Appendix I: Named Reactions Single-Bond Forming Reactions Co
    Appendix I: Named Reactions 235 / 335 432 / 533 synthesis / / synthesis Covered in Covered Featured in problem set problem Single-bond forming reactions Grignard reaction various Radical couplings hirstutene Conjugate addition / Michael reaction strychnine Stork enamine additions Aldol-type reactions (incl. Mukaiyama aldol) various (aldol / Claisen / Knoevenagel / Mannich / Henry etc.) Asymmetric aldol reactions: Evans / Carreira etc. saframycin A Organocatalytic asymmetric aldol saframycin A Pseudoephedrine glycinamide alkylation saframycin A Prins reaction Prins-pinacol reaction problem set # 2 Morita-Baylis-Hillman reaction McMurry condensation Gabriel synthesis problem set #3 Double-bond forming reactions Wittig reaction prostaglandin Horner-Wadsworth-Emmons reaction prostaglandin Still-Gennari olefination general discussion Julia olefination and heteroaryl variants within the Corey-Winter olefination prostaglandin Peterson olefination synthesis Barton extrusion reaction Tebbe olefination / other methylene-forming reactions tetrodotoxin hirstutene / Selenoxide elimination tetrodotoxin Burgess dehydration problem set # 3 Electrocyclic reactions and related transformations Diels-Alder reaction problem set # 1 Asymmetric Diels-Alder reaction prostaglandin Ene reaction problem set # 3 1,3-dipolar cycloadditions various [2,3] sigmatropic rearrangement various Cope rearrangement periplanone Claisen rearrangement hirstutene Oxidations – Also See Handout # 1 Swern-type oxidations (Swern / Moffatt / Parikh-Doering etc. N1999A2 Jones oxidation
    [Show full text]
  • Opinion of the Scientific Committee on Consumer Safety on O
    SCCS/1613/19 Final Opinion Version S Scientific Committee on Consumer Safety SCCS OPINION ON the safety of aluminium in cosmetic products Submission II The SCCS adopted this document at its plenary meeting on 03-04 March 2020 SCCS/1613/19 Final Opinion Opinion on the safety of aluminium in cosmetic products – submission II ___________________________________________________________________________________________ ACKNOWLEDGMENTS Members of the Working Group are acknowledged for their valuable contribution to this Opinion. The members of the Working Group are: For the preliminary and the final versions SCCS members Dr U. Bernauer Dr L. Bodin (Rapporteur) Prof. Q. Chaudhry (SCCS Chair) Prof. P.J. Coenraads (SCCS Vice-Chair and Chairperson of the WG) Prof. M. Dusinska Dr J. Ezendam Dr E. Gaffet Prof. C. L. Galli Dr B. Granum Prof. E. Panteri Prof. V. Rogiers (SCCS Vice-Chair) Dr Ch. Rousselle Dr M. Stepnik Prof. T. Vanhaecke Dr S. Wijnhoven SCCS external experts Dr A. Koutsodimou Dr A. Simonnard Prof. W. Uter All Declarations of Working Group members are available on the following webpage: http://ec.europa.eu/health/scientific_committees/experts/declarations/sccs_en.htm This Opinion has been subject to a commenting period of a minimum eight weeks after its initial publication (from 16 December 2019 until 17 February 2020). Comments received during this time period are considered by the SCCS. For this Opinion, some changes occurred, in particular in sections 1, 3.2, 3.3.4.5, 3.3.8.1, 3.5, as well as in related discussion parts and conclusion (question 1). The list of references has also been updated.
    [Show full text]
  • Vr Meds Ex01 3B 0825S Coding Manual Supplement Page 1
    vr_meds_ex01_3b_0825s Coding Manual Supplement MEDNAME OTHER_CODE ATC_CODE SYSTEM THER_GP PHRM_GP CHEM_GP SODIUM FLUORIDE A12CD01 A01AA01 A A01 A01A A01AA SODIUM MONOFLUOROPHOSPHATE A12CD02 A01AA02 A A01 A01A A01AA HYDROGEN PEROXIDE D08AX01 A01AB02 A A01 A01A A01AB HYDROGEN PEROXIDE S02AA06 A01AB02 A A01 A01A A01AB CHLORHEXIDINE B05CA02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D08AC02 A01AB03 A A01 A01A A01AB CHLORHEXIDINE D09AA12 A01AB03 A A01 A01A A01AB CHLORHEXIDINE R02AA05 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S01AX09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S02AA09 A01AB03 A A01 A01A A01AB CHLORHEXIDINE S03AA04 A01AB03 A A01 A01A A01AB AMPHOTERICIN B A07AA07 A01AB04 A A01 A01A A01AB AMPHOTERICIN B G01AA03 A01AB04 A A01 A01A A01AB AMPHOTERICIN B J02AA01 A01AB04 A A01 A01A A01AB POLYNOXYLIN D01AE05 A01AB05 A A01 A01A A01AB OXYQUINOLINE D08AH03 A01AB07 A A01 A01A A01AB OXYQUINOLINE G01AC30 A01AB07 A A01 A01A A01AB OXYQUINOLINE R02AA14 A01AB07 A A01 A01A A01AB NEOMYCIN A07AA01 A01AB08 A A01 A01A A01AB NEOMYCIN B05CA09 A01AB08 A A01 A01A A01AB NEOMYCIN D06AX04 A01AB08 A A01 A01A A01AB NEOMYCIN J01GB05 A01AB08 A A01 A01A A01AB NEOMYCIN R02AB01 A01AB08 A A01 A01A A01AB NEOMYCIN S01AA03 A01AB08 A A01 A01A A01AB NEOMYCIN S02AA07 A01AB08 A A01 A01A A01AB NEOMYCIN S03AA01 A01AB08 A A01 A01A A01AB MICONAZOLE A07AC01 A01AB09 A A01 A01A A01AB MICONAZOLE D01AC02 A01AB09 A A01 A01A A01AB MICONAZOLE G01AF04 A01AB09 A A01 A01A A01AB MICONAZOLE J02AB01 A01AB09 A A01 A01A A01AB MICONAZOLE S02AA13 A01AB09 A A01 A01A A01AB NATAMYCIN A07AA03 A01AB10 A A01
    [Show full text]